Melodi Health Announces $10.75 Million in Series A Funding, First Enrollment in Pivotal Clinical Trial
Summary
Ground-breaking investigational product from Melodi Health is designed to reduce post-surgical infections and other complications for breast cancer patientsMINNEAPOLIS, Aug. 29, 2024 /PRNewswire/ -- Melodi Health, a medical device company, announced two milestones today: the close of a $10.75 million oversubscribed Series A financing; and the launch of the "ARIA" investigational device exemption (IDE) trial aimed at improving clinical outcomes for women undergoing breast reconstruction after mastectomy. "We are thrilled to achieve these important financial and clinical milestones, namely the first implant of a device being evaluated for safety and efficacy that is designed to provide soft-tissue support and reduce post-surgical infections associated with breast cancer surgery," said Sarah Worrell, co-founder and CEO of Melodi Health. The Melodi Matrix, an absorbable mesh that is designed to support soft tissue while providing controlled release of antibiotic agents as it is absorbed into the body, is an implantable medical device comprised of proprietary technology licensed from Medtronic by Melodi Health.Melodis first patient was enrolled at University of Utah Health. "A 10-14% national average infection rate in breast reconstruction is not acceptable," said Alvin Kwok, MD, associate professor of surgery and principal investigator at University of Utah Health. "About MelodiMelodi Health is committed to transforming breast reconstruction through surgical innovation with the aim to meaningfully improve outcomes in a patient population that is undergoing complicated treatment regimens.